A
VRCA icon

AlphaQuest’s Verrica Pharmaceuticals VRCA Stock Holding History

AlphaQuest’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-693
Closed -$50.5K – 2000
2024
Q2 		$50.5K Buy
+693
New +$53.2K 0.01% 1067

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AlphaQuest's VRCA Position: Q3 2024 in Review

AlphaQuest sold out of Verrica Pharmaceuticals (VRCA) in Q3 2024, closing a stake of 693 shares — an estimated $50.5K sold.

AlphaQuest first reported a position in VRCA in Q2 2024 and held it in 1 quarter. The position peaked at $50.5K in Q2 2024. 79 funds tracked by Wall St. Rank hold VRCA as of Q3 2024.

  • AlphaQuest reported no remaining Verrica Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • AlphaQuest sold 693 Verrica Pharmaceuticals shares in Q3 2024, an estimated $50.5K.
  • AlphaQuest first reported a position in Verrica Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • AlphaQuest's Verrica Pharmaceuticals position peaked at $50.5K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2024.

Based on AlphaQuest's 13F filing for Q3 2024, filed 7 Nov 2024.